Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 893191 | ISIN: DK0011048619 | Ticker: 2P4
Frankfurt
18.11.26 | 09:02
0,115 Euro
-1,71 % -0,002
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOPORTO A/S Chart 1 Jahr
5-Tage-Chart
BIOPORTO A/S 5-Tage-Chart

Aktuelle News zur BIOPORTO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
28.09.BioPorto A/S: Unlocking the Growth - Invitation to BioPorto's investor meeting on October 73
BIOPORTO Aktie jetzt für 0€ handeln
24.09.BioPorto A/S: Reminder: Register Now | Unlocking the Growth - BioPorto Investor Meeting, October 71
16.09.BioPorto A/S: First Patient In - BioPorto Initiates Patient Enrollment as part of the ProNephro AKI U.S. Adult Urine NGAL Validation Study.183September 16, 2026News Release First Patient In - BioPorto Initiates Patient Enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL Validation Study. COPENHAGEN, DENMARK, September 16, 2026...
► Artikel lesen
14.09.BioPorto A/S: Unlocking the Growth - Invitation to BioPorto's investor meeting on Oct 71
20.08.BioPorto A/S: BioPorto announces Interim Results for the Second Quarter and First half of 2026365August 20, 2026Announcement no. 14 BioPorto announces Interim Results for the Second Quarter and First half of 2026 Copenhagen, Denmark, August 20, 2026, (GLOBE NEWSWIRE) - BioPorto A/S CVR-no. 17500317...
► Artikel lesen
18.08.BioPorto A/S: BioPorto activates the first US clinical site as part of the ProNephro AKI U.S. Adult Urine NGAL Validation Study.249August 18, 2026Press Release BioPorto activates the first US clinical site as part of the ProNephro AKI, U.S. Adult Urine NGAL Validation Study. COPENHAGEN, DENMARK, August 18, 2026 - BioPorto A/S...
► Artikel lesen
12.08.BioPorto A/S to host an investor webcast on the results for the first half of 20261
15.06.BioPorto A/S: Grant of Warrants1
09.06.BioPorto A/S: BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback604June 9, 2026Announcement no. 12 BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback COPENHAGEN, DENMARK, June 9, 2026 - BioPorto A/S ("BioPorto"...
► Artikel lesen
21.05.BioPorto A/S: BioPorto announces Interim Result for the First Quarter of 2026308May 21, 2026Announcement no. 11BioPorto announces Interim Result for the First Quarter of 2026 Copenhagen, Denmark, May 21, 2026, (GLOBE NEWSWIRE) - BioPorto A/S CVR-no. 17500317 (BioPorto or Company)...
► Artikel lesen
24.04.BioPorto A/S: Resolutions of the Annual General Meeting485April 24, 2026Announcement no. 10 Resolutions of the Annual General Meeting COPENHAGEN, DENMARK and BOSTON, MA, USA, April 24, 2026, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH: BIOPOR)...
► Artikel lesen
08.04.BioPorto A/S: BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC487April 8, 2026 Company Announcement No. 7 BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC COPENHAGEN, DENMARK and BOSTON, MA, USA, April 8, 2026 - BioPorto...
► Artikel lesen
31.03.BioPorto A/S: BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis469March 31, 2026Announcement no. 6 BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis COPENHAGEN, DENMARK, 31 March 2026 - BioPorto...
► Artikel lesen
26.03.BioPorto A/S: BioPorto announces the Annual Report for 2025437March 26, 2026Announcement no. 04BioPorto announces the Annual Report for 2025 Copenhagen, Denmark, March 26, 2026, (GLOBE NEWSWIRE) - BioPorto A/S CVR-no. 17500317 (BioPorto or company) (CPH:BIOPOR)...
► Artikel lesen
18.03.BioPorto A/S: BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026330March 18, 2026Announcement no. 03 BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026 COPENHAGEN, DENMARK, March 18, 2026...
► Artikel lesen
09.02.BioPorto A/S Appoints Chief Financial Officer335February 9, 2026Announcement no. 2 BioPorto A/S Appoints Chief Financial Officer BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced the appointment of Klaus Juhl Wulff as its new Executive Vice...
► Artikel lesen
05.02.BioPorto A/S: BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update300February 5, 2026Announcement no. 1 BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update ...
► Artikel lesen
11.12.25BioPorto A/S: Changes to the Executive Management482December 11, 2025 Announcement no. 29Changes to the Executive Management COPENHAGEN, DENMARK and BOSTON, MA, USA, December 11, 2025 (GLOBE NEWSWIRE) - BioPorto A/S ("BioPorto") (CPH:BIOPOR) announced...
► Artikel lesen
24.11.25BioPorto A/S - admittance to trading and official listing of new shares due a private placement321The share capital of BioPorto A/S has been increased. The admittance to trading and official listing will take effect as of 26 November 2025 in the ISIN below. ISIN: DK0011048619 Name: BioPorto Volume...
► Artikel lesen
19.11.25BioPorto A/S: BioPorto Interim Result for the Third Quarter of 2025 - Continued progress and continued NGAL sales growth453November 19, 2025 Announcement no. 26 BioPorto Interim Result for the Third Quarter of 2025 - Continued progress and continued NGAL sales growth. Copenhagen, Denmark, November 19, 2025, (GLOBE NEWSWIRE)...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1